treatment with chloroquine. "-Our analysis suggests that there is also a high risk of severe cutaneous adverse reactions when Fansidar is used as monoprophylaxis.
Reactions to Fansidar
Seventy eight reactions in 52 Swedish travellers occurring between 1978 and the end of June 1985 were considered by the Swedish Adverse Drug Reactions Advisory Committee to have had a probable or possible causal relation with Fansidar. During the same period roughly 1-2 million tablets were sold in Sweden. All 52 travellers used Fansidar as monoprophylaxis, and only four took any other drugs. All except three took one tablet weekly. Four travellers had previously experienced adverse reactions to sulphonamides. Only three went to chloroquine resistant areas in Africa.
Skin reactions were reported in 24 travellers after a median of 13 days (range 1-45 days). Seven patients experienced severe cutaneous adverse reactions (table) Three cases of photosensitivity and 14 of exanthema were reported. None of the travellers who suffered cutaneous reactions had previously experienced adverse reactions to sulphonamides. Liver reactions occurred in 15 travellers (12 women), developing after a median of 52 days (range 16-91 days). Five had increased liver enzyme activities alone, while the others were also icteric. One of the eight travellers with respiratory symptoms (seven men) complained of dyspnoea and one had pleuritis, while the remaining six also suffered pulmonary infiltrations and fever. Symptoms occurred 1-30 days after treatment was started. Two men developed severe generalised vasculitis. One became ill with fever, orchitis, jaundice, cutaneous vasculitis, and gastrointestinal bleeding after two weeks. The other developed cutaneous vasculitis and rapidly progressive nephritis after three weeks. Severe megaloblastic anaemia was noted in one traveller after six weeks, one traveller experienced reversible hyperaesthesia, and one reported itching.
Comment
The true risk of adverse reactions is difficult to estimate. The duration of prophylaxis varies and many tablets are never used and some are prescribed for self treatment. In addition, many adverse reactions are never reported. Glibenclamide is a widely prescribed and well toleraced oral antidiabetic drug. We report a case of immune haemolytic anaemia associated with glibenclamide treatment in a patient with selective IgA deficiency.
Case report A 48 year old mentally retarded man with mild diabetes was given glibenclamide for two months. He had been taking zuclopenthixol for several years. During treatment with glibenclamide he became jaundiced and increasingly fatigued. Anaemia and a raised bilirubin concentration led to admission to hospital.
On examination he had icteric scleras but no fever, hepatosplenomegaly, or lymphadenopathy. Haemoglobin concentration was 85 g/l and red cell count 2-67x 1012/I with 58% reticulocytes. Erythrocyte sedimentation rate was 108 mm in the first hour, serum bilirubin concentration 59 iLmol/l, lactate dehydrogenase activity 6% IU/l, haptoglobin concentration <0-25 mg/I, and ferritin concentration 113 ,tg/l. A peripheral blood smear showed polychromasia, spherocytosis, anisocytosis, and some nucleated red blood cells. The white cell morphology was normal except for 16% eosinophils. A bone marrow specimen showed erythroid hyperplasia. A Paul-Bunnell test and a complement fixation test for mycoplasma antibodies gave negative results and cold agglutinins were not found. A direct Coombs test gave strongly positive results with anti-IgG and weakly positive results with anti-C3 and anti-C4. Serum IgG concentration was 8-9 g/l, IgM 1-7 g/l, C3 0-75 g/l, C4 0-24 g/l, and IgE <5 x 103 U/I. IgA could not be shown in the serum (<0-006 g/l). Tests for antinuclear and rheumatoid factors gave negative results.
After one week in hospital the patient's haemoglobin concentration had fallen to 78 g/l, and he received three units ofblood. As this resulted in only a temporary increase in haemoglobin concentration glibenclamide was stopped. A few days later the blood variables began to improve, and on follow up examination five weeks later haemoglobin concentration was 132 g/l, erythrocyte sedimentation rate 24 mm in the first hour, and red cell count 4-62x 1012/1 with 23% reticulocytes. His diabetes was well controlled by diet alone.
His serum did not agglutinate normal red cells in vitro, and no agglutination occurred when glibenclamide at various concentrations was added to the serum.
Six months later, a Coombs test with anti-IgG still gave strongly positive results, but negative results were obtained with anti-C3 and anti-C4. There was no haemolysis.
The rapid and complete recovery when glibenclamide was stopped strongly suggests that this drug caused the immune haemolytic anaemia.
The neuroleptic treatment was continued, and the patient had not received any other drugs before admission. Although a wide variety of drugs may induce haemolysis,' sulphonylureas have seldom been found responsible. 2 3 The Committee on Safety of Medicines and the manufacturer have not received any reports of a possible association between glibenclamide and haemolytic anaemia (personal communication). Logue et al described immune haemolytic anaemia in a patient treated with chlorpropamide; in vitro testing showed cross reactivity with glibenclamide and related compounds. Immune haemolysis in vivo caused by glibenclamide, however, does not seem to have been reported before. The usual neurological manifestations are fluctuating symptoms of meningoencephalitis with superimposed cranial or peripheral radiculopathy, but although these features are often intermittent, the duration ofmeningitic symptoms is more like that of chronic meningitis. 4 We report on a patient with Lyme disease who presented with recurrent acute meningitis and no history of tick bite, cutaneous eruptions, or other systemic symptoms.
Case report
A 55 year old man was admitted in October 1984 with a history offeeling unwell and occipital headaches for two days. He was feverish, and clinical examination showed only slight stiffness of the neck on extreme flexion.
Investigations showed a normal full blood count. Studies ofcerebrospinal fluid showed a raised protein concentration (2-4 g/l), a glucose concentration of 5 3 mmolIl, and 240x 109 leucocytes/l (100%b lymphocytes); tests for the presence of bacteria, fungi, and viruses yielded negative results. He was treated with intravenous penicillin 16 megaunits daily for seven days and recovered completely within the next few days. Sixteen months later he was admitted withsimilar symptoms of short duration and slight stiffness of the neck. Cerebrospinal fluid studies showed a raised protein concentration (0-8 g/l), a glucose concentration of 5-8 mmoUl, and lymphocytes< lx 109'/; cultures yielded negative results.
He recovered spontaneously within a few days without any specific treatment.
Seven months later he again presented with similar symptoms of one day's duration; examination showed a fever (38°C) with slight stiffness of the neck but no other physical abnormality. Cerebrospinal fluid contained 60x 109 leucocytes/l (95% polymorphs); the protein concentration was 1-8 g/l and glucose concentration 4-2 mmolIl. Cultures for Mycobaterium tuberculosis and tests for fungi and viruses yielded negative results. A repeat examination of cerebrospinal fluid after seven days showed 196x 109 leucocytes/l (100% lymphocytes), a protein concentration of 1-13 g/l, and a glucose concentration of4-7 mmol/l. A computed tomogram of the brain showed no abnormality. Intravenous penicillin 16 megaunits daily was started on the second day of admission, and he made a complete recovery within the next 24 hours. Treatment was continued for two weeks, and he had no further complications. An indirect immunofluorescence test for antibodies to Borrelia bu:rgdorferi yielded a positive result. Sevsen weeks after admission his serum IgG titre was 1/256 and IgM titre negative. A further sample of serum 10 days later had an IgG titre of 1/64 and a negative IgM titre.
Comment
Our patient had two symptom free periods of 16 and seven months, respectively, between three episodes of acute meningitis. Serological tests were done only during the last admission. Although we cannot exclude the possibility of reinfection, which is known to occur in Lyme disease,5 we believe that these episodes were recurrences. The first episode occurred after the patient had worked on a road in a deer forest. He had not done this before the second and third episodes, and the presenting symptoms were similar on each admission. The subsequent episodes are therefore unlikely to have been due to reinfection as he did not develop the more common dermatological and systemic symptoms before either of them. Inadequate treatment of the first episode is also unlikely because the intervals between attacks were too long.
Recurrent meningitis is often difficult to diagnose. The natural course of bacterial, fungal, and viral meningitis is well understood, but in some cases it may be exceptionally difficult to establish the source ofinfection. When only neurological symptoms are present a diagnosis of Lyme disease may not be obvious. 2 Patients with recurrent episodes of aseptic meningitis should have serological tests for B burgdorferi even if there is no history of tick bite or cutaneous lesions; if Lyme disease is diagnosed early high dose intravenous penicillin can shorten the duration ofmeningitic symptoms.
Increased sexual drive may be common in patients with Parkinson's disease receiving treatment with levodopa ordopamine agonists.' The incidence ofa true "aphrodisiac" effect, however, is difficult to assess. Frankly hypersexual or deviant behaviour occurs rarely and is usually associated with an acute brain syndrome or history of hypersexuality. 2 Though diminished libido is a common feature of Parkinson's disease,3 impotence related to dopaminergic treatment has not been reported. We describe four men with idiopathic Parkinson's disease with no history of sexual difficulty who spontaneously complained of impotence associated with dopamine agonist (bromocriptine) treatment.
Case reports
Case I-A 59 year old man was receiving treatment with incremental doses of bromocriptine. After seven months, when the total daily dose was increased from 45 mg to 60 mg and good control of the parkinsonian symptoms had been gained, he became impotent. In spite of noticeably increased sexual urge he achieved erections only transiently and penetration was impossible. When the dose was reduced to 30 mg daily erectile function returned to normal, with worsening of the parkinsonian symptoms. Subsequent increases in the dose of bromocriptine invariably produced impotence. A combined regimen, however, of levodopa (Sinemet-Plus, one tablet three times daily) and bromocriptine (5 mg three times daily) resulted in good control of Parkinson's disease and normal sexual drive and erectile function.
Case 2-A 34 year old man was receiving incremental doses of bromocriptine. After four months (22-5 mg daily) he experienced inability to sustain erections.
When the dose was reduced to 11-~25 mg daily normal sexual function returned
